HGF/c-Met related activation of β-catenin in hepatoblastoma

BackgroundActivation of beta-catenin is a hallmark of hepatoblastoma (HB) and appears to play a crucial role in its pathogenesis. While aberrant accumulation of the beta-catenin is a common event in HB, mutations or deletions in CTNNB1 (beta-catenin gene) do not always account for the high frequency of protein expression. In this study we have investigated alternative activation of beta-catenin by HGF/c-Met signaling in a large cohort of 98 HB patients enrolled in the SIOPEL-3 clinical trial.MethodsWe performed immunohistochemistry, using antibodies to total beta-catenin and tyrosine654-phosphorylated beta-catenin, which is a good surrogate marker of HGF/c-Met activation. CTNNB1 mutation analysis was also carried out on all samples. We also investigated beta-catenin pathway activation in two liver cancer cell lines, HuH-6 and HuH-7.ResultsAberrant beta-catenin expression was seen in the cytoplasm and/or nucleus of 87% of tumour samples. Our results also revealed a large subset of HB, 83%, with cytoplasmic expression of tyrosine654-phosphorylated beta-catenin and 30% showing additional nuclear accumulation. Sequence analysis revealed mutations in 15% of our cohort. Statistical analysis showed an association between nuclear expression of c-Met-activated beta-catenin and wild type CTNNB1 (P-value = 0.015). Analysis of total beta-catenin and Y654-beta-catenin in response to HGF activation in the cell lines, mirrors that observed in our HB tumour cohort.ResultsWe identified a significant subset of hepatoblastoma patients for whom targeting of the c-Met pathway may be a treatment option and also demonstrate distinct mechanisms of beta-catenin activation in HB.

[1]  J. Ritz,et al.  Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Morin,et al.  beta-catenin signaling and cancer. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[3]  T. Asahara,et al.  Accumulation of β-Catenin Protein and Mutations in Exon 3 of β-Catenin Gene in Gastrointestinal Carcinoid Tumor , 2001 .

[4]  A. Feinberg,et al.  Loss of imprinting in hepatoblastoma. , 1995, Cancer research.

[5]  A. Zimmermann.  The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. , 2005, European journal of cancer.

[6]  B. Morland,et al.  Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. , 2009, The New England journal of medicine.

[7]  R. Nusse,et al.  Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.

[8]  M. Buendia.  Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. , 2002, Medical and pediatric oncology.

[9]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[10]  A. Bell,et al.  Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. , 2002, Cancer research.

[11]  A. Bell,et al.  Hepatocyte Growth Factor Induces Wnt-independent Nuclear Translocation of β-Catenin after Met-β-Catenin Dissociation in Hepatocytes , 2002 .

[12]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[13]  Y. Arai,et al.  Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma , 2008, British Journal of Cancer.

[14]  B. Cieply,et al.  Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene , 2009, Hepatology.

[15]  A. Okada,et al.  High frequency of beta-catenin mutations in hepatoblastoma. , 2001, Pediatric surgery international.

[16]  A. Bell,et al.  Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. , 2006, Experimental cell research.

[17]  T. Faraggiana,et al.  Frequent β-catenin overexpression without exon 3 mutation in cutaneous lymphomas , 2004, Modern Pathology.

[18]  A. Bell,et al.  Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. , 2006, Neoplasia.

[19]  M. Buendia,et al.  Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. , 2000, Oncogene.

[20]  D. V. von Schweinitz,et al.  The occurrence of liver growth factor in hepatoblastoma. , 1998, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

[21]  D. Bottaro,et al.  Targeting the c-Met signaling pathway in cancer. , 2008, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  A. Bell,et al.  Tyrosine residues 654 and 670 in β-catenin are crucial in regulation of Met–β-catenin interactions , 2006 .

[23]  D. Nelson,et al.  Stabilized β-catenin promotes hepatocyte proliferation and inhibits TNFα-induced apoptosis , 2004, Laboratory Investigation.

[24]  B. Pollock,et al.  The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. , 2005, The Journal of pediatrics.

[25]  G. Chenevix-Trench,et al.  β‐Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours , 1999, International journal of cancer.

[26]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[27]  A. Zimmermann.  Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways. , 2002, Medical and pediatric oncology.

[28]  P. Gunaratne,et al.  Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. , 2009, Human pathology.

[29]  Nan Faion T. Wu,et al.  The Beckwith-Wiedemann Syndrome , 1974, Clinical pediatrics.

[30]  G. Perilongo,et al.  SIOPEL trials using preoperative chemotherapy in hepatoblastoma. , 2000, The Lancet. Oncology.

[31]  S. Ranganathan,et al.  β-Catenin and Met Deregulation in Childhood Hepatoblastomas , 2005 .

[32]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[33]  T. Asahara,et al.  Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. , 2001, Cancer research.

[34]  M. Buendia,et al.  Activation of β-catenin in epithelial and mesenchymal hepatoblastomas , 2000, Oncogene.

[35]  S. Monga,et al.  Wnt/β-catenin signaling in hepatic organogenesis , 2008 .

[36]  S. Ranganathan,et al.  beta-Catenin and met deregulation in childhood Hepatoblastomas. , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[37]  J Pritchard,et al.  Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.

[38]  Christopher Lawrence.  Pathology , 1911, The Lancet.

[39]  R. Mariani-Costantini,et al.  Sporadic childhood hepatoblastomas show activation of β-catenin, mismatch repair defects and p53 mutations , 2008, Modern Pathology.

[40]  A. Bell,et al.  Aberrant Wnt/β-Catenin Signaling in Pancreatic Adenocarcinoma , 2006 .

[41]  T. Faraggiana,et al.  Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. , 2004, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[42]  E. Hiyama,et al.  Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. , 2006, Oncology reports.

[43]  K. Furuuchi,et al.  Nuclear accumulation of beta-catenin without an additional somatic mutation in coding region of the APC gene in hepatoblastoma from a familial adenomatous polyposis patient. , 2004, Oncology reports.

[44]  A. Okada,et al.  High frequency of β-catenin mutations in hepatoblastoma , 2001, Pediatric Surgery International.

[45]  B. Cieply,et al.  beta-Catenin is critical for early postnatal liver growth. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[46]  Y. Jeng,et al.  Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. , 2000, Cancer letters.

[47]  S. Albrecht,et al.  Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. , 1999, Cancer research.

[48]  D. Kimelman,et al.  β-Catenin destruction complex: insights and questions from a structural perspective , 2006, Oncogene.

[49]  G. Perilongo,et al.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Gunaratne,et al.  Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. , 2009, Human pathology.

[51]  Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. , 2004, Laboratory investigation; a journal of technical methods and pathology.

[52]  R. Penzel,et al.  β‐catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma , 1999, Genes, chromosomes & cancer.

[53]  H. S. Kim,et al.  Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. , 2001, The Journal of pathology.

[54]  David I. Smith,et al.  Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.

[55]  A. Nakagawara,et al.  Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  A. Koch,et al.  Hepatocyte growth‐factor‐scatter factor can stimulate post‐operative tumor‐cell proliferation in childhood hepatoblastoma , 2000, International journal of cancer.

[57]  S. Monga,et al.  Wnt/beta-catenin signaling in hepatic organogenesis. , 2008, Organogenesis.

[58]  R. Weksberg,et al.  Beckwith–Wiedemann syndrome , 2010, European Journal of Human Genetics.

[59]  B. Zbar,et al.  Oncogenic Mutants of RON and MET Receptor Tyrosine Kinases Cause Activation of the β-Catenin Pathway , 2001, Molecular and Cellular Biology.